ClinicalTrials.gg
RecruitingNCT07507799Updated Sep 2, 2026

Low Versus Standard Volume EXORA Block in Laparoscopic Cholecystectomy

An interventional study of EXORA block 15 and EXORA block 25 in Pain, Postoperative and Post Operative Analgesia, sponsored by Fayoum University Hospital. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Fayoum University Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Pain, Postoperative by Fayoum University Hospital — 4 open to participants now, 4 under way, none of them phase 3. Pain, Postoperative · Fayoum University Hospital.

Planned enrollment
5th of 17
96 · median 66
Started
2026
with 2 others
No phase
14 of 17
4 open now
Registered
16th of 17
by date

Among the 17 studies in Pain, Postoperative by Fayoum University Hospital, this one is the 5th largest by planned enrollment, is one of 3 that started in 2026, is one of 14 with no phase, and was the 16th registered.

Pain, Postoperative

5,675 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

4 of the 17 studies in Pain, Postoperative by Fayoum University Hospital are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Pain, Postoperative by Fayoum University Hospital, or all of them as a file.
02

Study summary

The original EXORA block used high local anesthetic volume (50 mL total), raising concerns about local anesthetic systemic toxicity (LAST). In such a bilaterally administered regional technique, evaluating the efficacy of a reduced-volume approach is warranted to maximize patient safety.

Read the detailed description

Study Design \& Population This is a prospective, randomized, double-blinded trial enrolling patients scheduled for elective laparoscopic cholecystectomy. Following informed consent, patients will be randomly allocated into two equal groups to evaluate different volumes used in a bilateral, ultrasound-guided External Oblique and Rectus Abdominis (EXORA) block.

Interventions Prior to the induction of general anesthesia, patients will receive a bilateral EXORA block using 0.25% bupivacaine.

Group E15: Will receive 15 mL of the local anesthetic on each side. Group E25: Will receive 25 mL of the local anesthetic on each side. Blinding \& Allocation Allocation concealment will be maintained using sequentially numbered, opaque, sealed envelopes. The block will be performed by a designated regional anesthesiologist who will not be involved in subsequent patient care. The patient, the surgical team, the intraoperative anesthesiologist, and the postoperative data collectors will remain strictly blinded to the group allocation and the volume injected.

Anesthesia \& Perioperative Management Sensory block distribution will be assessed prior to surgery. All patients will receive a standardized general anesthesia protocol for induction and maintenance. Intraoperative hemodynamics will be managed according to standard institutional protocols.

Postoperative Analgesia \& Monitoring Upon transfer to the Post-Anesthesia Care Unit (PACU) and throughout the first 24 hours, all patients will receive scheduled, standardized multimodal analgesia (intravenous paracetamol and ketorolac). Postoperative pain will be assessed using the 11-point Numerical Rating Scale (NRS) at rest and during movement at prespecified time points. If the dynamic NRS score is ≥ 4, intravenous morphine (2 mg) will be administered . Patients will be continuously monitored for adverse events, including postoperative nausea and vomiting (PONV), hemodynamic instability, and local anesthetic systemic toxicity (LAST), which will be managed with predefined rescue medications

03

Conditions studied

  • Pain, Postoperative
  • Post Operative Analgesia

Browse trials for

Keywords

  • EXORA
  • analgesic efficacy
  • low volume
  • laparoscopic cholecystectomy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ASA) physical status I or II.
  • Scheduled for elective laparoscopic cholecystectomy under general anesthesia.

Exclusion criteria

Exclusion Criteria:

    • Patient refusal to participate.

      • Obese patients with a of more than 35 kg/m2.
      • Known cognitive impairment or use of psychiatric drugs
      • Known allergy to local anesthetics
      • Infection at the needle insertion site.
      • Coagulopathy, or bleeding disorders.
      • Pregnancy
      • History of chronic pain or chronic opioid use.
      • Previous major upper abdominal surgery (which alters the fascial planes and anatomy).

Criteria for Withdrawal from Study Analysis (Drop-outs):

  • Conversion to open cholecystectomy during surgery.
  • Failed EXORA block
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
96 participants (estimated)

Study arms

  • Active comparator
    EXORA 15

    15 mL of bupivacaine 0.25% administered bilaterally

    Procedure: EXORA block 15

  • Active comparator
    EXORA 25

    25 mL of bupivacaine 0.25% administered bilaterally

    Procedure: EXORA block 25

Interventions

  • ProcedureEXORA block 15

    15 mL of bupivacaine 0.25% administered bilaterally by ultrasound guided EXORA block

  • ProcedureEXORA block 25

    25 mL of bupivacaine 0.25% administered bilaterally by ultrasound guided EXORA block

06

What researchers measure

Primary outcomes

  1. Dynamic numerical rating scale (NRS) score at 4 hours postoperatively.

    From 0 to 10 where 0 denote no pain and 10 denote the worst pain ever experienced with cough

    Time frame: 4 hours after surgery

Secondary outcomes

  1. Static Numerical Rating scale NRS scores

    From 0 to 10 where 0 denote no pain and 10 denote the worst pain ever experienced At predefined time points.(1,2,4,6,12 and 24 hours post operatively

    Time frame: up to 24 hours post operatively

  2. Dynamic numerical rating scale NRS scores

    From 0 to 10 where 0 denote no pain and 10 denote the worst pain ever experienced With cough at predefined time points.(1,2,6,12 and 24 hours post operatively

    Time frame: up to 24 hours post operatively

  3. Cumulative Static Pain Burden

    calculated as the Area Under the Curve (AUC) of Static NRS scores over the 24-hour postoperative period

    Time frame: Up to 24h postoperatively

  4. Cumulative Dynamic Pain Burden

    calculated as the Area Under the Curve (AUC) of Dynamic NRS scores over the 24-hour postoperative period

    Time frame: Up to 24h postoperatively

  5. Intraoperative Fentanyl consumption Total fentanyl in micrograms

    Total fentanyl in micrograms

    Time frame: From induction of anesthesia until patient is transferred to postoperative care unit up to 4 hours]

  6. Total cumulative consumption of intravenous morphine over the first 24 hours.

    total morphine used in milligrams post operatively over 24 hours.

    Time frame: At 24 hours postoperatively

  7. Time to first rescue analgesia

    Time to first request of rescue analgesia in hours

    Time frame: Upon recovery from General anesthesia up to 24 hours postoperatively]

  8. Sensory block distribution level (pin-prick test)

    After 30 minutes of the block, assessed at. Midclavicular and Midaxillary lines from T5 to T12 level by a blinded anesthesiologist

    Time frame: At 30 minuets from the block

  9. Quality of recovery score (QoR-15) at 24 hours.

    scores range from 0 to 150, with a higher score indicating a better quality of postoperative recovery.

    Time frame: At 24 hours postoperatively

  10. Incidence of adverse events: bradycardia, hypotension, PONV, and LAST.

    Assessment of each patient looking for any of adverse effects as bradycardia ,hypotension, nausea, vomiting and LAST.

    Time frame: From induction of anesthesia up to 24 hours postoperatively

  11. Heart rate

    Heart rate measured at Baseline (T0), 3 minutes post-intubation (T1), 1 minute post-skin incision (T2), 5 minutes after pneumoperitoneum inflation (T3), At extubation (T4) and postoperatively upon arrival in the PACU (0 hours), 1, 2, 4, 6, 12, and 24 hours

    Time frame: Upon arrival to Operating Room until 24 hours postoperative

  12. Mean arterial pressure

    Mean arterial pressure measured at Baseline (T0), 3 minutes post-intubation (T1), 1 minute post-skin incision (T2), 5 minutes after pneumoperitoneum inflation (T3), At extubation (T4) and postoperatively upon arrival in the PACU (0 hours), 1, 2, 4, 6, 12, and 24 hours

    Time frame: Upon arrival to Operating Room until 24 hours postoperative

  13. Ramsay Sedation Scale (RSS)

    from 1 to 6 where 1 denotes anxious/agitated and 6 denotes deep sedation with no response to stimuli (6) assessed postoperative (at 1, 2, 4, 6, 12, and 24 hours)

    Time frame: up to 24 hours

07

Study locations

1 of 1 sites recruiting
  • Fayoum University hospital
    El Fayoum Qesm, Faiyum Governorate 63514, Egypt
    Recruiting
    • Mohamed A Hamed, MD · Contactmah07@fayoum.edu.eg · 1010509736
    • Mohamed H Ragab, MD · Contactmhr02@fayoum.edu.eg · 1090050298
    • Mohamed A Hamed, MD · Principal investigator
    • Omar S Farghaly, MD · Sub investigator
    • Mohamed H Ragab, MD · Sub investigator
    • Mohammed R Gomaa, Bch · Sub investigator
08

References and documents

Publications

  • Okmen K, Demirel A, Dogan AK, Ertus CY. Application of EXORA block for analgesia following hand-assisted laparoscopic donor nephrectomy (HALDN). Indian J Anaesth. 2025 Mar;69(3):324-326. doi: 10.4103/ija.ija_1263_24. Epub 2025 Feb 17. No abstract available. PubMed 40161911 ↗
  • Okmen K, Yildiz DK, Ulker GK. Evaluation of the efficacy of M-TAPA and EXORA block application for analgesia after laparoscopic cholecystectomy: a prospective, single-blind, observational study. Korean J Anesthesiol. 2025 Aug;78(4):361-368. doi: 10.4097/kja.24563. Epub 2025 Apr 15. PubMed 40230270 ↗
  • Fernandez Martin MT, Lopez Alvarez S, Valdes-Vilches LF. EXORA block: a new approach for laparoscopic cholecystectomy analgesia? Minerva Anestesiol. 2024 May;90(5):462-463. doi: 10.23736/S0375-9393.23.17863-1. Epub 2024 Jan 29. No abstract available. PubMed 38287777 ↗
  • Kumar K, Kirksey MA, Duong S, Wu CL. A Review of Opioid-Sparing Modalities in Perioperative Pain Management: Methods to Decrease Opioid Use Postoperatively. Anesth Analg. 2017 Nov;125(5):1749-1760. doi: 10.1213/ANE.0000000000002497. PubMed 29049119 ↗
  • De Cassai A, Sella N, Geraldini F, Tulgar S, Ahiskalioglu A, Dost B, Manfrin S, Karapinar YE, Paganini G, Beldagli M, Luoni V, Ordulu BBK, Boscolo A, Navalesi P. Single-shot regional anesthesia for laparoscopic cholecystectomies: a systematic review and network meta-analysis. Korean J Anesthesiol. 2023 Feb;76(1):34-46. doi: 10.4097/kja.22366. Epub 2022 Nov 8. PubMed 36345156 ↗
  • Ekstein P, Szold A, Sagie B, Werbin N, Klausner JM, Weinbroum AA. Laparoscopic surgery may be associated with severe pain and high analgesia requirements in the immediate postoperative period. Ann Surg. 2006 Jan;243(1):41-6. doi: 10.1097/01.sla.0000193806.81428.6f. PubMed 16371735 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jan 2027, 8 months after the start.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 8 months is below that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2026
First posted
Apr 2, 2026
StartActual
Apr 12, 2026
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 2, 2027
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07507799
Lead sponsor
Fayoum University Hospital
Responsible party
Mohamed Ahmed Hamed (Professor of Anesthesiology, Fayoum University Hospital) — Principal investigator
First posted
Apr 2, 2026
Start date
Apr 12, 2026
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 2, 2027 (estimated)
Last update
Sep 2, 2026

Study contacts

Mohammed R Gomaa, Bch
Contact
mr147@fayoum.edu.eg
1097830069 ext. +20
Mohamed H Ragab, MD
Contact
mhr02@fayoum.edu.eg
1090050298 Ext. +20 ext. +20
Mohamed A Hamed,, MD
principal investigator · Faculty of medicine, Fayoum university

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion